INCY

A weekly deal roundup from Seeking Alpha highlights notable transactions and partnerships involving GSK, Incyte, Ingredion, OpenAI, and other companies. The article aggregates multiple deal events across sectors without providing detailed terms or outcomes for each. This is a curated recap of activity rather than a report on a single new development.

Incyte has announced a definitive agreement to acquire Vega Therapeutics for $1.25 billion. The deal represents a confirmed M&A transaction, adding Vega's pipeline to Incyte's portfolio. No additional financial terms or closing timeline were disclosed in the headline.

Incyte is reportedly nearing a deal to acquire Star Therapeutics, a blood disorder drug developer, for approximately $2 billion, according to the Financial Times. The deal has not been confirmed by either company. If completed, the acquisition would expand Incyte's hematology pipeline.

Incyte (INCY) is set to report Q1 2026 earnings with analyst consensus revenue expectations of $1.23 billion, supported by key products Jakafi and Opzelura alongside growing royalties and new product launches. The source-tagged ticker LLY (Eli Lilly) appears to be a tagging error, as the article focuses exclusively on Incyte. No specific earnings date or EPS estimates are provided in the article.